The growth law of primary breast cancer as inferred from mammography screening trials data.

Despite considerable progress in understanding tumour development, the law of growth for human tumours is still a matter of some dispute. In this study, we used large-scale mammography screening trial data to deduce the growth law of primary breast cancer. We compared the empirical tumour population size distributions of primary breast cancer inferred from these data to the distributions that correspond to various possible theoretical growth functions. From this, we showed that the data are inconsistent with the exponential, logistic and Gompertz laws, but support power law growth (exponent approximately 0.5). This law indicates unbounded growth but with slowing mass-specific growth rate and doubling time. In the clinical size ranges, it implies a greater decline in the mass-specific growth rate than would be predicted by the Gompertz law using the accepted parameters. This suggests that large tumours would be less sensitive to cycle-specific therapies, and be better treated first by non-cell cycle-specific agents. We discussed the use of our study to estimate the sensitivity of mammography for the detection of small tumours. For example, we estimated that mammography is about 30% less sensitive in the detection of tumours in the 1 to 1.5-cm range than it is in detecting larger tumours.

[1]  L. Tabár,et al.  Update of the Swedish two-county program of mammographic screening for breast cancer. , 1992, Radiologic clinics of North America.

[2]  P. Haccou Mathematical Models of Biology , 2022 .

[3]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[4]  J. Crown High-dose chemotherapy of metastatic breast cancer: the end of the beginning? , 1997, British Journal of Cancer.

[5]  J. McCaskill,et al.  Monte Carlo approach to tissue-cell populations. , 1995, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[6]  J. Spratt,et al.  Growth rates of primary breast cancers , 1979, Cancer.

[7]  H. D. de Koning,et al.  Nation‐wide breast cancer screening in the Netherlands: Support for breast‐cancer mortality reduction , 1995, International journal of cancer.

[8]  S. Feig,et al.  Analysis of clinically occult and mammographically occult breast tumors. , 1977, AJR. American journal of roentgenology.

[9]  Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness. , 1994, Journal of the National Cancer Institute.

[10]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[11]  T. Hislop,et al.  The British Columbia Mammography Screening Program: evaluation of the first 15 months. , 1992, AJR. American journal of roentgenology.

[12]  J. Gershon-Cohen,et al.  Roentgenography of breast cancer moderating concept of “Biologic predeterminism” , 1963, Cancer.

[13]  L. Schiffer,et al.  The cell kinetics of human mammary cancers , 1979, Cancer.

[14]  G. Sanguineti,et al.  In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Steel,et al.  The growth rate of human tumours. , 1966, British Journal of Cancer.

[16]  Laird Ak Dynamics of Tumour Growth: Comparison of Growth Rates and Extrapolation of Growth Curve to One Cell , 1965 .

[17]  L. Tabár,et al.  SURVIVAL IN BREAST CANCER DIAGNOSED BETWEEN MAMMOGRAPHIC SCREENING EXAMINATIONS , 1986, The Lancet.

[18]  Roland Holland,et al.  Age‐dependent growth rate of primary breast cancer , 1993, Cancer.

[19]  L. Norton A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[20]  M L Mendelsohn,et al.  Analysis of tumor growth curves. , 1968, Journal of the National Cancer Institute.

[21]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.